Bronchiectasis: The EMBARC Manual
Editat de James Chalmers, Eva Polverino, Stefano Alibertien Limba Engleză Paperback – 6 iun 2019
While non–cystic fibrosis bronchiectasis was formerly regarded as an “orphan” disease, international data reveal an increase in its prevalence in recent years. Accordingly, there has been renewed interest in the disease, resulting in more clinical research and the development of new treatments. The impact of bronchiectasis on healthcare systems is substantial and it has a clear attributable mortality. In covering all aspects of the disease, this book will be of interest to respiratory, internal medicine, and infectious disease fellows as well as specialists, final-year medical students, nurses and physiotherapists. The authors are leading experts and chairs of the steering committee of EMBARC, the first truly international bronchiectasis network.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 549.33 lei 38-44 zile | |
Springer International Publishing – 6 iun 2019 | 549.33 lei 38-44 zile | |
Hardback (1) | 803.09 lei 38-44 zile | |
Springer International Publishing – 24 ian 2018 | 803.09 lei 38-44 zile |
Preț: 549.33 lei
Preț vechi: 578.24 lei
-5% Nou
Puncte Express: 824
Preț estimativ în valută:
105.13€ • 109.20$ • 87.33£
105.13€ • 109.20$ • 87.33£
Carte tipărită la comandă
Livrare economică 29 ianuarie-04 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319870830
ISBN-10: 3319870831
Pagini: 342
Ilustrații: VIII, 342 p. 58 illus., 27 illus. in color.
Dimensiuni: 155 x 235 x 24 mm
Greutate: 0.73 kg
Ediția:Softcover reprint of the original 1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319870831
Pagini: 342
Ilustrații: VIII, 342 p. 58 illus., 27 illus. in color.
Dimensiuni: 155 x 235 x 24 mm
Greutate: 0.73 kg
Ediția:Softcover reprint of the original 1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
Preface.- Introduction.- 1 Radiological diagnosis of bronchiectasis.- 2 Epidemiology and clinical aspects.- 3 Pathophysiology and histopathology of bronchiectasis.- 4 Immunology of bronchiectasis.- 5 How to identify treatable causes and other predisposing factors in bronchiectasis.- 6 Immunodeficit in bronchiectasis.- 7 ENT diseases and bronchiectasis.- 8 Bronchiectasis and ABPA.- 9 COPD and bronchiectasis.- 10 Other predisposing factors for bronchiectasis.- 11 Channelopathies in bronchiectasis.- 12 The severity of the disease and multidisciplinary management.- 13 Pseudomonas aeruginosa in bronchiectasis.- 14 The role of other bacteria, fungi and viruses in bronchiectasis.- 15 NTM in bronchiectasis.- 16 Exacerbation of bronchiectasis.- 17 Long-tern inhaled antibiotic treatment.- 18 Long-term oral antibiotic / anti-inflammatory treatment.- 19 Airway clearance.- 20 Pulmonary rehabilitation.- 21 Nursing management.- 22 Surgery and transplantation in bronchiectasis.- 23 How to manage bronchiectasis in primary care.- 24 An overview of bronchiectasis in children.- Conclusions.
Recenzii
“This is excellently written book provides an up-to-date and concise summary of our current understanding of bronchiectasis as well as highlighting gaps in our knowledge and where we should target research efforts in the future. … This is book will provide a valuable reference for health-care professionals looking for succinct, up-to-date information to help them holistically investigate and manage their patients with bronchiectasis.” (J.K. Quin, British Journal of Hospital Medicine, Vol. 79 (6), June, 2018)
Notă biografică
Dr James D Chalmers is Senior Clinical Lecturer and Consultant Physician at the Scottish Centre for Respiratory Research at the University of Dundee. He runs a large specialist bronchiectasis clinic in the East of Scotland and a research group focussing on the interactions between neutrophil mediated inflammation and bacterial infection in chronic respiratory disease, particularly bronchiectasis and COPD. He is associated editor of the European Respiratory Journal and a member of the international advisory board of the Lancet Respiratory Medicine. He is chair of the European Bronchiectasis Network and Registry (EMBARC).
Eva Polverino is Doctor of Medicine in Cardiopulmonary Pathophysiology from the University of Pisa (Italy). She currently works as postdoctoral clinical researcher at the Hospital Clinic in Barcelona, IDIBAPS. Specialist in respiratory medicine, she is involved in the field of respiratory infections and particularly in Community Acquired Pneumonia (CAP), noncystic fibrosis bronchiectasis (NCFB) and humoral immuno-deficiencies. She investigates epidemiology, risk factors, outcome, treatment and prevention of the most relevant respiratory infections. In the field of bronchiectasis main objectives are focused on investigation of the prevalence and outcomes of this underestimated but very frequent disease, and its impact on the society. The results of her research are aimed at investigating pathogenetic mechanisms of respiratory infections, improving their clinical outcomes and patients’ quality of life.
Stefano Aliberti is Associate Professor of Respiratory Medicine at the University of Milan and consultant at the Cardio-Thoracic Unit and Cystic Fibrosis Adult Center at the Policlinico Hospital in Milan, Italy. His research interest is in respiratory infectious diseases, including bronchiectasis, NTM and pneumonia. He has published extensively in this area over the past 10 years as well as co-authoring books and book chapters on respiratory medicine. He is Head of the Respiratory Infection Assembly of the European Respiratory Society. He is chair of EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration), director of the Italian Registry of Bronchiectasis IRIDE and the Italian Registry of pulmonary NTM IRENE.
Eva Polverino is Doctor of Medicine in Cardiopulmonary Pathophysiology from the University of Pisa (Italy). She currently works as postdoctoral clinical researcher at the Hospital Clinic in Barcelona, IDIBAPS. Specialist in respiratory medicine, she is involved in the field of respiratory infections and particularly in Community Acquired Pneumonia (CAP), noncystic fibrosis bronchiectasis (NCFB) and humoral immuno-deficiencies. She investigates epidemiology, risk factors, outcome, treatment and prevention of the most relevant respiratory infections. In the field of bronchiectasis main objectives are focused on investigation of the prevalence and outcomes of this underestimated but very frequent disease, and its impact on the society. The results of her research are aimed at investigating pathogenetic mechanisms of respiratory infections, improving their clinical outcomes and patients’ quality of life.
Stefano Aliberti is Associate Professor of Respiratory Medicine at the University of Milan and consultant at the Cardio-Thoracic Unit and Cystic Fibrosis Adult Center at the Policlinico Hospital in Milan, Italy. His research interest is in respiratory infectious diseases, including bronchiectasis, NTM and pneumonia. He has published extensively in this area over the past 10 years as well as co-authoring books and book chapters on respiratory medicine. He is Head of the Respiratory Infection Assembly of the European Respiratory Society. He is chair of EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration), director of the Italian Registry of Bronchiectasis IRIDE and the Italian Registry of pulmonary NTM IRENE.
Textul de pe ultima copertă
This book presents state of the art knowledge and practice in the rapidly developing field of bronchiectasis not due to cystic fibrosis (referred to below simply as bronchiectasis). The focus is especially on diagnosis and existing and emerging therapies, but the book also covers a wide range of other key topics, from pathophysiology, histopathology, and immunology through to pulmonary rehabilitation, nursing care, and management in primary care and pediatric settings.
While bronchiectasis was formerly regarded as an “orphan” disease, international data reveal an increase in its prevalence in recent years. Accordingly, there has been renewed interest in the disease, resulting in more clinical research and the development of new treatments. The impact of bronchiectasis on healthcare systems is substantial and it has a clear attributable mortality. In covering all aspects of the disease, this book will be of interest to respiratory, internal medicine, and infectious disease fellowsand specialists, final-year medical students, and nurses and physiotherapists. The authors are leading experts and chairs of the steering committee of EMBARC, the first truly international bronchiectasis network.
While bronchiectasis was formerly regarded as an “orphan” disease, international data reveal an increase in its prevalence in recent years. Accordingly, there has been renewed interest in the disease, resulting in more clinical research and the development of new treatments. The impact of bronchiectasis on healthcare systems is substantial and it has a clear attributable mortality. In covering all aspects of the disease, this book will be of interest to respiratory, internal medicine, and infectious disease fellowsand specialists, final-year medical students, and nurses and physiotherapists. The authors are leading experts and chairs of the steering committee of EMBARC, the first truly international bronchiectasis network.
Caracteristici
Covers all aspects of bronchiectasis Presents the state of the art in diagnosis and treatment Written by international experts on bronchiectasis